Before PSM, the BRAF V600E mutation was detected in postoperative pathological specimens from 252 patients with thyroid cancer, of which 73.0% (184/252) were the mutant type and 27% (68/252) were the wild type (shown in Table 1). Here, BRAF is linked to thyroid cancer.